PathologyWatch, the leading US digital laboratory and pathology platform for dermatologists, has raised $25 million financing from a range of new and existing investors.
With the new funding, PathologyWatch will broaden its outreach to dermatologists and conduct further research into skincare diagnostics and artificial intelligence (AI), allowing patients to receive faster diagnoses and more equitable access to dermatopathology services while enabling laboratories to work more efficiently and cost-effectively. Additionally, the funding will support operations as the business expands across the country, adding new laboratories in Texas, Florida, and Arizona.
PathologyWatch provides fully interfaced EMR reporting and 24/7 access to digital slides for dermatology clinics. For clients, this means more efficient workflows and direct access to leading dermatopathologists across the country, with broad insurance coverage. PathologyWatch has successfully integrated laboratory information systems, scanners, digital viewer technology, and EMRs into an end-to-end solution for dermatologists.